KneeDaily · 膝关节运动医学文献获取 App

工程化异体FE002-Cart软骨祖细胞球体用于大面积膝关节软骨缺损:微环境信号对功能调控、GMP制剂及物流可行性的研究

Pharmaceutics · 2026-Aug-20
阅读数 0
Applegate Lee Ann, Hadjab Farid, Jaccoud Sandra, Porcello Alexandre, Philippe Virginie, Hirt-Burri Nathalie et al.

简介

该体外研究开发了一种无支架三维同种异体FE002-Cart软骨祖细胞球体,用于修复大面积膝关节软骨缺损。结果显示,在2%低氧并严格限制地塞米松(10 nM)的微环境下,球体GAG沉积显著增加,ACAN、COL2表达上调逾200倍,单位细胞GAG产量达传统MACI支架平台的10倍,且较成人自体软骨细胞表型更稳定,对骨关节炎滑液环境有较强耐受。研究为未来“即用型…

英文摘要

Background: The clinical translation of cell-based therapies for knee articular cartilage repair is fundamentally restricted by the severe biological unpredictability of autologous cell sources, inherent manufacturing bottlenecks, and the rapid phenotypic dedifferentiation of cells expanded in conventional 2D monolayers. To overcome these translational hurdles, this study engineered a scaffold-free, 3D formulation of highly characterized allogeneic FE002-Cart chondroprogenitor spheroids. Methods: We systematically investigated the specific microenvironmental cues and Good Manufacturing Practice (GMP) formulation parameters required to direct functional chondrogenesis. The structural and biochemical performance of this allogeneic formulation was benchmarked against multiple primary adult autologous chondrocyte types. Finally, we evaluated the phenotypic resilience of the microtissues in simulated osteoarthritic (OA) environments and investigated both short-term liquid storage and advanced terminal preservation strategies to establish off-the-shelf logistical viability. Results: Precise microenvironmental regulation proved to be a critical biological prerequisite. The synergistic combination of physiological hypoxia (2% O2) and stringent glucocorticoid limitation (10 nM dexamethasone) induced robust glycosaminoglycan (GAG) deposition and a > 200-fold upregulation of ACAN and COL2, while suppressing the terminal hypertrophic drift observed in adult chondrocytes. Benchmarking revealed that the allogeneic FE002-Cart formulation substantially mitigates the profound morphological and biochemical unpredictability inherent to adult autologous cell sources. Furthermore, the scaffold-free spheroid geometry yielded a 10-fold increase in GAG production per cell compared to traditional matrix-seeded (MACI) platforms. Transitioning to a GMP-compatible manufacturing process revealed extreme cellular sensitivities; excipients within standard pharmaceutical-grade dexamethasone severely aborted chondrogenic differentiation, emphasizing the necessity of rigorous raw-material qualification. Functionally, the 3D architecture acted as a protective physical shield, sustaining high cellular viability when subjected to severe inflammatory stress and 100% OA patient synovial fluid. Logistically, the viable spheroids maintained matrix integrity and inter-spheroid fusion potential for up to 7 days at ambient temperature in transport medium. Finally, advanced spheroid preservation via lyophilization and high-dose gamma irradiation eliminated biological viability but successfully transitioned the microtissues into highly organized, terminally irradiated matrices capable of heterologous in vitro structural merging. Conclusions: These findings define the critical biological thresholds for manufacturing, demonstrate the enhanced in vitro biosynthetic efficiency of 3D allogeneic microtissues compared to specific autologous and matrix-dependent baselines, and establish a highly practical, off-the-shelf logistical framework for the regenerative treatment of large knee chondral defects.

关键词

advanced therapy medicinal products (ATMP) allogeneic cytotherapies cartilage tissue engineering cell formulation chondrogenesis good manufacturing practice (GMP) hypoxia manufacturing process off-the-shelf implants three-dimensional spheroids

链接

获取 KneeDaily

选择手机系统

iPhone前往 App Store ↗ 安卓查看下载与安装说明 →
微信内无法打开?

在微信右上角菜单选择“在浏览器打开”,或复制下面的网址到浏览器。

https://kneedaily.com/kneedaily